CONTEXT: Little is known about symptom burden-a concept encompassing both symptom severity and the degree of symptom interference with daily living-in patients with cancer in Morocco or other countries with Arabic-speaking populations. OBJECTIVES: The goal of this study was to psychometrically validate the Arabic version of the M. D. Anderson Symptom Inventory (MDASI-A), a tool for measuring multiple symptoms in patients with cancer, and to test its utility in a sample of patients with late-stage cancer in Morocco. METHODS: The MDASI-A was developed by standard forward-backward translation of the English MDASI. We used nonidiomatic Arabic in the MDASI-A to enhance its possible usefulness for all Arabic-speaking patients with cancer. One hundred sixty-five Arabic-speaking patients with various cancer types were recruited from a city hospital in Rabat, Morocco. The MDASI-A was administered by interview, as only 5% of the patients had a high school education. RESULTS: Psychometric analysis demonstrated acceptable internal consistency, with Cronbach alpha values of 0.85 for all 19 items, 0.78 for symptom severity items, and 0.79 for interference items; known-group validity was demonstrated by significant differences in mean symptom severity and interference between patients with good vs. poor performance status. All patients had moderate to severe pain and were taking pain medications. Additional severe symptoms included fatigue, lack of appetite, and disturbed sleep. Patients with gastrointestinal or gynecological cancer reported relatively more symptom severity than patients with breast or lung cancer. Poor performance status, male gender, and current infection were significant predictors of high symptom interference (R(2)=0.48, P<0.05). CONCLUSION: The MDASI-A is a valid and reliable patient-reported outcome instrument that can be used to assess Moroccan Arabic-speaking cancer patients' multiple symptoms. Its utility for use in other Arab countries needs to be tested. Copyright 2010 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.
CONTEXT: Little is known about symptom burden-a concept encompassing both symptom severity and the degree of symptom interference with daily living-in patients with cancer in Morocco or other countries with Arabic-speaking populations. OBJECTIVES: The goal of this study was to psychometrically validate the Arabic version of the M. D. Anderson Symptom Inventory (MDASI-A), a tool for measuring multiple symptoms in patients with cancer, and to test its utility in a sample of patients with late-stage cancer in Morocco. METHODS: The MDASI-A was developed by standard forward-backward translation of the English MDASI. We used nonidiomatic Arabic in the MDASI-A to enhance its possible usefulness for all Arabic-speaking patients with cancer. One hundred sixty-five Arabic-speaking patients with various cancer types were recruited from a city hospital in Rabat, Morocco. The MDASI-A was administered by interview, as only 5% of the patients had a high school education. RESULTS: Psychometric analysis demonstrated acceptable internal consistency, with Cronbach alpha values of 0.85 for all 19 items, 0.78 for symptom severity items, and 0.79 for interference items; known-group validity was demonstrated by significant differences in mean symptom severity and interference between patients with good vs. poor performance status. All patients had moderate to severe pain and were taking pain medications. Additional severe symptoms included fatigue, lack of appetite, and disturbed sleep. Patients with gastrointestinal or gynecological cancer reported relatively more symptom severity than patients with breast or lung cancer. Poor performance status, male gender, and current infection were significant predictors of high symptom interference (R(2)=0.48, P<0.05). CONCLUSION: The MDASI-A is a valid and reliable patient-reported outcome instrument that can be used to assess Moroccan Arabic-speaking cancerpatients' multiple symptoms. Its utility for use in other Arab countries needs to be tested. Copyright 2010 U.S. CancerPain Relief Committee. Published by Elsevier Inc. All rights reserved.
Authors: Tito R Mendoza; Xin Shelley Wang; Charles Lu; Guadalupe R Palos; Zhongxing Liao; Gary M Mobley; Shitij Kapoor; Charles S Cleeland Journal: Oncologist Date: 2011-02-01
Authors: Carolyn Miller Reilly; Deborah Watkins Bruner; Sandra A Mitchell; Lori M Minasian; Ethan Basch; Amylou C Dueck; David Cella; Bryce B Reeve Journal: Support Care Cancer Date: 2013-01-12 Impact factor: 3.603
Authors: Desiree Jones; Elisabeth G Vichaya; Charles S Cleeland; Lorenzo Cohen; Seema M Thekdi; Xin Shelley Wang; Michael J Fisch Journal: J Oncol Pract Date: 2013-11-26 Impact factor: 3.840
Authors: Mary H Sailors; Diane C Bodurka; Ibrahima Gning; Lois M Ramondetta; Loretta A Williams; Tito R Mendoza; Sonika Agarwal; Charlotte C Sun; Charles S Cleeland Journal: Gynecol Oncol Date: 2013-05-15 Impact factor: 5.482
Authors: Desiree Jones; Elisabeth G Vichaya; Xin Shelley Wang; Loretta A Williams; Nina D Shah; Sheeba K Thomas; Valen E Johnson; Richard E Champlin; Charles S Cleeland; Tito R Mendoza Journal: J Hematol Oncol Date: 2013-02-05 Impact factor: 17.388